Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 20, 2002, Pages 2935-2939

  Palle, Venkata P ^a   Elzein, Elfatih O ^a   Gothe, Scott A ^b   Li, Zhihe ^a   Gao, Zhenhai ^a   Meyer, Stephanie ^a   Blackburn, Brent ^a   Zablocki, Jeff A ^a  

^a CV THERAPEUTICS INC   (United States)

^b TRIPOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (N 1 PYRAZOLYL)ADENOSINE; 2 PYRAZOLYLADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE DERIVATIVE; FUNCTIONAL GROUP; NITROGEN; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG STRUCTURE; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADENOSINE; BINDING SITES; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS;

EID: 0037152455     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00609-1     Document Type: Article

References (22)

1. Müller C.E. Farmaco. 56:2001;77.
2. Pavan B., Ijzerman A.P. Biochem. Pharmacol. 56:1998;1625.
3. Shryock J.C., Belardinelli L. Am. J. Cardiol. 79:1997;2.
4. Snowdy S., Liang H.X., Blackburn B., Lum R., Nelson M., Wang L., Pfister J., Sharma B.P., Wolff A., Belardinelli L. Br. J. Pharmacol. 126:1999;137.
5. Shryock J.C., Snowdy S., Baraldi P.G., Cacciari B., Spalluto G., Monopoli A., Ongini E., Baker S.P., Belardinelli L. Circulation. 98:1998;711.
6. Gao Z., Li Z., Baker S.P., Lasley R.D., Meyer S., Elzein E., Palle V., Zablocki J.A., Blackburn B., Belardinelli L.J. Pharmacol. Exp. Ther. 298:2001;209.
7. Glover D.K., Ruiz M., Yang J.Y., Koplan B.A., Allen T.R., Smith W.H., Watson D.D., Barrett R.J., Beller G.A. Circulation. 94:1996;1726.
8. Fozard J.R., Ellis K.M., Villela Dantas M.F., Tigani B., Mazzoni L. Eur. J. Pharmacol. 438:2002;183.
9. Feoktistov I., Biaggioni I. Pharmacol. Rev. 49:1997;381.
10. Liang J.T., Jacobson K.A. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6995.
11. Matsuda A., Shinozaki M., Yamaguki T., Homma H., Nomoto R., Miyasaka T., Watanabe Y., Abiru T. J. Med. Chem. 35:1992;241.
12. Vittori S., Camaioni E., Di Francesco E., Volpini R., Monopoli A., Dionisotti S., Ongini E., Cristalli G. J. Med. Chem. 39:1996;4211.
13. Francis J., Webb R., Ghai G., Hutchison A., Moskal M., deJesus R., Yokoyama R., Rovinski S., Contardo N., Dotson R., Barclay B., Stone G., Jarvis M. J. Med. Chem. 34:1991;2570.
14. Niiya K., Olsson R., Thompson R., Silvia S., Ueeda M. J. Med. Chem. 35:1992;4557.
15. Zablocki J., Palle V., Blackburn B., Elzein E., Nudelman G., Gothe S., Gao Z., Li Z., Meyer S., Belardinelli L. Nucleosides Nucleotides. 20:2001;343.
16. Bertz H., Dabbagh G., Cotte P. J. Org. Chem. 47:1982;2216.
17. To a suspension of 2-hydrazinoadenosine (0.025 g, 0.08 mmol) in a 1:1 mixture of MeOH/AcOH was added 2-(4-methyl)malondialdehyde (0.019 g, 0.12 mmol) and the mixture was heated at 80°C for 3 h. The precipitate formed was collected by filtration and washed with EtOH and ether and dried.
18. The acid 38 was synthesized as follows: The ester 2 (0.50 g, 1.2 mmol) was dissolved in 30 mL DMF. To the solution was added imidazole (0.68 g, 10 mmol) and TBDMSCl (1.5 g, 10 mmol). The mixture was allowed to stir at 80°C for 24 h. The solvent was removed and the residue was purified using column chromatography to afford the trisilyl-protected derivative of 2.
19. Kato K., Hayakawa H., Tanaka H., Kumamoto H., Miyasaka T. Tetrahedron Lett. 36:1995;6507.
20. For review, Mitchell T.N. Synthesis. 803:1992;. (Stille).
21. Zhang W., Robins M.J. Tetrahedron Lett. 33:1992;1177.
22. Molecular modeling was performed using a Sybyl 6.6 program wherein the torsional angle about the pyrazolyl-purine bond was optimized to a local minima using the advanced computational module searching at 15 rotational degrees followed by alignment of the comparator compound using the Fit Algorithm within Sybyl.